M. A. Gall
Novo Nordisk
6 Papers
M. A. Gall is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 6, co-authored 6 publications. Previous affiliations of M. A. Gall include Aarhus University.
Chat about Author
Papers
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
TL;DR: This study compared the effect of insulin detemir on glycaemic control with that of Neutral Protamine Hagedorn human isophane (NPH) insulin, both combined with insulin aspart, in children with Type 1 diabetes mellitus, and compared the safety of these treatments.
149
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
Thomas R. Pieber,Treichel Hc,Hompesch B,Areti Philotheou,L. Mordhorst,M. A. Gall,L.I. Robertson +6 more
TL;DR: The objective is to compare glycaemic control and risk of hypoglycaemia of twice‐daily insulin detemir with once‐ daily insulin glargine in subjects with Type 1 diabetes.
Safety and efficacy of inhaled insulin (AERx((R)) iDMS(1)) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial
R. G. Moses,P. Bartley,Helen Lunt,Richard C O'Brien,T. Donnelly,M. A. Gall,A. Vesterager,Per Wollmer,A. Roberts +8 more
TL;DR: Assessment of the long‐term safety and efficacy of liquid inhaled insulin via AERx® insulin Diabetes Management System (iDMS) in a basal/bolus treatment regimen of adults with Type 1 diabetes.
The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency
Torben Østergård,Kristine B. Degn,M. A. Gall,Richard D. Carr,Johannes D. Veldhuis,Mads Krogsgaard Thomsen,Robert A. Rizza,Ole Schmitz +7 more
TL;DR: The present experimental design does not support the hypothesis that acute administration of pharmacological doses of the oral antihyperglycemic agents glibenclamide and repaglinide per se enhance GH release in humans, and shows that these potassium channel inhibitors seem to stimulate glucagon secretion in people who have severe intraislet insulin deficiency.
Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Malene Hollingdal,Jeppe Sturis,Jeppe Sturis,M. A. Gall,M. A. Gall,P. Damsbo,P. Damsbo,Steven M. Pincus,Johannes D. Veldhuis,Johannes D. Veldhuis,Niels Pørksen,Ole Schmitz,Claus B. Juhl +12 more
TL;DR: The present study was undertaken to explore a possible influence of the oral prandial glucose regulator, repaglinide, on first‐phase insulin secretion and high‐frequency insulin pulsatility in Type 2 diabetes.